These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27633417)

  • 1. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
    Choe H; Ruan J
    Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting indolent non-Hodgkin lymphoma.
    Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
    Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breakthrough therapies in B-cell non-Hodgkin lymphoma.
    Cheah CY; Fowler NH; Wang ML
    Ann Oncol; 2016 May; 27(5):778-87. PubMed ID: 26802148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs for the treatment of non-Hodgkin lymphomas.
    Smith SM
    Chin Clin Oncol; 2015 Mar; 4(1):14. PubMed ID: 25841721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
    Jahangiri S; Friedberg J; Barr P
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction inhibitors in chronic lymphocytic leukemia.
    Ma S; Rosen ST
    Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
    Rosenthal A
    Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Kienle DL; Stilgenbauer S
    Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinate PI3K pathway and Bcl-2 family disruption in AML.
    Bose P; Rahmani M; Grant S
    Oncotarget; 2012 Dec; 3(12):1499-500. PubMed ID: 23439314
    [No Abstract]   [Full Text] [Related]  

  • 14. B-cell receptor pathobiology and targeting in NHL.
    Macias-Perez IM; Flinn IW
    Curr Oncol Rep; 2012 Oct; 14(5):411-8. PubMed ID: 22865093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
    Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
    Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
    Zhu J; Hou T; Mao X
    Drug Discov Today; 2015 Aug; 20(8):988-94. PubMed ID: 25857437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
    Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
    Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.